Atrial natriuretic factor (ANF) in experimental and human hypertension.
The plasma levels of immunoreactive (IR)-ANF have been evaluated by radioimmunoassay in several models of experimental hypertension and in human hypertension. In all models of experimental hypertension so far studied, the plasma levels of IR-ANF are consistently increased. This is accompanied by a decrease, at certain time intervals, of the IR-ANF levels in the left atrium. In human essential hypertension, the plasma levels of IR-ANF are not increased except in the severe form (diastolic blood pressure above 110 mmHg). In renovascular hypertension, the peripheral levels of IR-ANF are not different from the normal levels but are increased above normal in aortic blood.
Cantin
M
M
Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, Quebec, Canada.
Garcia
R
R
Thibault
G
G
Kuchel
O
O
Gutkowska
J
J
Larochelle
P
P
Hamet
P
P
Schiffrin
E L
EL
Genest
J
J
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000032:analysis / Q000097:blood* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006325:Heart Atria / Q000032:analysis; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D006978:Hypertension, Renovascular / Q000097:blood; D008297:Male; D011863:Radioimmunoassay; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D012504:Saralasin / Q000494:pharmacology; D013564:Sympathetic Nervous System / Q000503:physiopathology
C472955:NPPA protein, human; D009320:Atrial Natriuretic Factor; D012504:Saralasin